INT70878

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.75
First Reported 1997
Last Reported 2008
Negated 1
Speculated 0
Reported most in Body
Documents 17
Total Number 18
Disease Relevance 4.25
Pain Relevance 2.02

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (CYP2A6) endoplasmic reticulum (CYP2A6) enzyme binding (CYP2A6)
Anatomy Link Frequency
liver 1
Caco-2 1
1A2 1
alveolar macrophages 1
kidney 1
CYP2A6 (Homo sapiens)
Pain Link Frequency Relevance Heat
Nicotine 438 99.66 Very High Very High Very High
dopamine receptor 42 99.36 Very High Very High Very High
Serotonin 126 98.36 Very High Very High Very High
rapifen 7 97.82 Very High Very High Very High
Dextromethorphan 1 96.60 Very High Very High Very High
alcohol 29 94.76 High High
Paracetamol 4 92.44 High High
Antiepileptic agent 1 75.00 Quite High
Potency 10 72.80 Quite High
tolerance 8 70.56 Quite High
Disease Link Frequency Relevance Heat
Disease 285 98.92 Very High Very High Very High
Nicotine Addiction 893 98.04 Very High Very High Very High
Lung Cancer 18 97.68 Very High Very High Very High
Repression 3 95.68 Very High Very High Very High
Autoimmune Hepatitis 507 94.20 High High
Liver Disease 27 91.88 High High
Primary Sclerosing Cholangitis 21 85.52 High High
Autoimmune Disease 30 76.80 Quite High
Headache 2 70.04 Quite High
Hepatitis 55 68.76 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In the present study, we detected expression of CYP2A6/7 in both alveolar macrophages and bronchial biopsy material, but we did not find any difference in regard to smoking status.
Gene_expression (expression) of CYP2A6 in alveolar macrophages associated with nicotine addiction
1) Confidence 0.75 Published 2006 Journal Environ Health Perspect Section Body Doc Link PMC1665420 Disease Relevance 0.55 Pain Relevance 0
The somewhat high interindividual variation of CYP2A6/7 gene expression observed in the present study and in the study of Crawford et al. (1998) make comparison of the data difficult.
Gene_expression (expression) of CYP2A6
2) Confidence 0.75 Published 2006 Journal Environ Health Perspect Section Body Doc Link PMC1665420 Disease Relevance 0.57 Pain Relevance 0
Expression of CYP1A1 (p < 0.01), CYP1B1 (p < 0.001), and CYP2S1 (p < 0.001) was higher in BAL cells from smokers compared with those of nonsmokers (Figure 1), whereas expression of CYP2B6/7 (p < 0.01) and CYP3A5 (p < 0.001) was lower; expression of CYP2A6/7, CYP2E1, CYP2C9, CYP2J2, and FMO5 was not altered.
Gene_expression (expression) of CYP2A6 associated with nicotine addiction
3) Confidence 0.75 Published 2006 Journal Environ Health Perspect Section Body Doc Link PMC1665420 Disease Relevance 0.75 Pain Relevance 0
CYP2A6, a protein with minor pharmacological implication, also was induced by eletriptan and rifampicin in two cultures but was not detected in the others.
Neg (not) Gene_expression (detected) of CYP2A6
4) Confidence 0.68 Published 2000 Journal Drug Metab. Dispos. Section Abstract Doc Link 10611140 Disease Relevance 0.07 Pain Relevance 0.17
These transformants are designated Hepc/1A1.4, Hepc/1A2.9, Hepc/2A6L.14, Hepc/2B6.68, Hepc/2C8.46, Hepc/2C9.1, Hepc/2C19.12, Hepc/2D6.39, Hepc/2E1.3-8 and Hepc/3A4.2-30, which stably expressed human CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4, respectively.
Gene_expression (expressed) of CYP2A6 in 1A2
5) Confidence 0.62 Published 2001 Journal Toxicol In Vitro Section Abstract Doc Link 11377097 Disease Relevance 0 Pain Relevance 0
Although environmental compounds can affect its activity, either inducing the enzyme (e.g., phenobarbital) or decreasing its expression (e.g., nicotine) [130,131], the CYP2A6 gene also expresses genetic polymorphisms that may contribute to the variation in nicotine metabolism and therefore smoking behavior.
Gene_expression (expresses) of CYP2A6 associated with nicotine addiction and nicotine
6) Confidence 0.49 Published 2004 Journal Tob Induc Dis Section Body Doc Link PMC2671538 Disease Relevance 0.16 Pain Relevance 0.37
Although environmental compounds can affect its activity, either inducing the enzyme (e.g., phenobarbital) or decreasing its expression (e.g., nicotine) [130,131], the CYP2A6 gene also expresses genetic polymorphisms that may contribute to the variation in nicotine metabolism and therefore smoking behavior.
Gene_expression (expresses) of CYP2A6 associated with nicotine addiction and nicotine
7) Confidence 0.49 Published 2004 Journal Tob Induc Dis Section Body Doc Link PMC2669467 Disease Relevance 0.16 Pain Relevance 0.37
For several key enzymes, CYP1A2, CYP2A6, CYP2C19 and CYP2E1, these ratios were particularly low (?
Gene_expression (enzymes) of CYP2A6
8) Confidence 0.44 Published 2008 Journal Proceedings of the Royal Society B: Biological Sciences Section Body Doc Link PMC2367444 Disease Relevance 0 Pain Relevance 0
CYP2A6 is less researched, but is important here as the principal metabolizing enzyme of nicotine.
Gene_expression (researched) of CYP2A6 associated with nicotine
9) Confidence 0.44 Published 2008 Journal Proceedings of the Royal Society B: Biological Sciences Section Body Doc Link PMC2367444 Disease Relevance 0 Pain Relevance 0.11
Cholinergic receptor nicotinic beta polypeptide 2, serotonin receptor and transporter genes, dopamine receptor and transporter genes, and the cytochrome P450A6 gene are reviewed.
Gene_expression (reviewed) of cytochrome P450A6 gene associated with dopamine receptor and serotonin
10) Confidence 0.43 Published 2004 Journal Tob Induc Dis Section Abstract Doc Link PMC2669467 Disease Relevance 0 Pain Relevance 0.14
Cholinergic receptor nicotinic beta polypeptide 2, serotonin receptor and transporter genes, dopamine receptor and transporter genes, and the cytochrome P450A6 gene are reviewed.
Gene_expression (reviewed) of cytochrome P450A6 gene associated with dopamine receptor and serotonin
11) Confidence 0.43 Published 2004 Journal Tob Induc Dis Section Abstract Doc Link PMC2671538 Disease Relevance 0 Pain Relevance 0.14
Selected compounds were screened for cytochrome P450 inhibition (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4), metabolic stability (rat and human liver microsomes), and cell-membrane permeability (Caco-2).
Gene_expression (screened) of CYP2A6 in Caco-2
12) Confidence 0.32 Published 2006 Journal ChemMedChem Section Abstract Doc Link 16892345 Disease Relevance 0 Pain Relevance 0.03
The following specific assays were investigated: testosterone 6beta-hydroxylation [cytochrome P-450 3A4 (CYP3A4)], coumarin hydroxylation (CYP2A6), (R)-warfarin hydroxylation (CYP1A2), (S)-mephenytoin hydroxylation (CYP2C19), p-nitrophenol hydroxylation (CYP2E1) tolbutamide hydroxylation (CYP2C9), dextromethorphan O-demethylation (CYP2D6), epoxide hydrolase and UDP-glucuronyltransferase (UGT) toward paracetamol (UGT1*6), ethinyloestradiol (UGT1*1), p-nitrophenol (UGT(pl 6.2)), and valproic acid.
Gene_expression (hydroxylation) of CYP2A6 associated with paracetamol and dextromethorphan
13) Confidence 0.31 Published 1999 Journal Drug Metab. Dispos. Section Abstract Doc Link 9929511 Disease Relevance 0 Pain Relevance 0.21
Microsomes prepared from different human liver samples were compared for their abilities to metabolize fentanyl, sufentanil and alfentanil, and it was found that disappearance of the three substrates was well correlated with immunoreactive CYP3A4 contents but not with other CYPs, including CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2D6 and CYP2E1.
Gene_expression (contents) of CYP2A6 in liver associated with rapifen
14) Confidence 0.21 Published 1997 Journal Biochem. Pharmacol. Section Abstract Doc Link 9264313 Disease Relevance 0 Pain Relevance 0.38
CYP1A2, CYP2A6, CYP21, CYP17, and CYP11A1), that are expressed in organs affected by the disease process.
Gene_expression (expressed) of CYP2A6 associated with disease
15) Confidence 0.20 Published 2004 Journal J Autoimmune Dis Section Body Doc Link PMC544946 Disease Relevance 1.25 Pain Relevance 0.04
Among the four autoantibodies anti-CYP2A6 were detected with the highest prevalence in a Finnish APECED patients group (15.6%), while anti-CYP1A2 were found in 6.3% [23].
Gene_expression (detected) of CYP2A6
16) Confidence 0.20 Published 2004 Journal J Autoimmune Dis Section Body Doc Link PMC544946 Disease Relevance 0.41 Pain Relevance 0
CYP1A1, CYP2A6 and CYP2B6 are expressed both in liver and in kidney resulting to an LKM staining pattern, while CYP1A2 is not expressed in the kidney leading to the LM staining.
Gene_expression (expressed) of CYP2A6 in kidney
17) Confidence 0.20 Published 2004 Journal J Autoimmune Dis Section Body Doc Link PMC544946 Disease Relevance 0.32 Pain Relevance 0
The principal enzymes with polymorphic variants involved in phase I reactions are the following: CYP3A4/5/7, CYP2E1, CYP2D6, CYP2C19, CYP2C9, CYP2C8, CYP2B6, CYP2A6, CYP1B1, CYP1A1/2, epoxide hydrolase, esterases, NQO1 (NADPH-quinone oxidoreductase), DPD (dihydropyrimidine dehydrogenase), ADH (alcohol dehydrogenase), and ALDH (aldehyde dehydrogenase).
Gene_expression (/) of CYP2A6 associated with alcohol
18) Confidence 0.16 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2654795 Disease Relevance 0 Pain Relevance 0.07

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox